Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Cancer Immunol Res. 2015 Jan 19;3(4):356–367. doi: 10.1158/2326-6066.CIR-14-0186

Figure 7. A-C. In vivo efficacy of c-Met IgG4 28ζ CAR T cells.

Figure 7

CD4+ and CD8+ T cells transduced to express CD19 IgG4 28ζ or c-Met IgG4 28ζ CAR under the influence of either EF-1α promoter or PGK100 promoter were infused (two administrations, 16 × 106 cells in total) into mice (for no T cells n=2; for the rest n=8 per group) bearing intraperitoneal SKOV3 tumors pre-established for 16 days. (A) Bioluminescence signal was acquired every week as a surrogate for tumor growth. p < 0.01 EF-1α vs PGK100 group. (B) Kaplan-Meier analysis. * indicates p < 0.05, EF-1α vs PGK100, log-rank (Mantel-Cox) test was used for statistical analysis. (C) The absolute number of human CD45+ T cells was determined in the blood on days 37 (left panel) and 73 (right panel), respectively. Only 2 mice survived in the EF-1α c-Met IgG4 28ζ CAR group on d73. * indicates p < 0.05. Two-tailed student T-test was used for statistical analysis. The design of the CAR constructs is shown in Supplemental Figure S1.